» Articles » PMID: 33653351

Comprehensive Analysis of the Transcriptome-wide MA Methylome in Invasive Malignant Pleomorphic Adenoma

Overview
Journal Cancer Cell Int
Publisher Biomed Central
Date 2021 Mar 3
PMID 33653351
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Invasive malignant pleomorphic adenoma (IMPA) is a highly invasive parotid gland tumor and lacks effective therapy. N6-Methyladenosine (mA) is the most prevalent post-transcriptional modification of mRNAs in eukaryotes and plays an important role in the pathogenesis of multiple tumors. However, the significance of mA-modified mRNAs in IMPA has not been elucidated to date. Hence, in this study, we attempted to profile the effect of IMPA in terms of mA methylation in mRNA.

Methods: Methylated RNA immunoprecipitation with next-generation sequencing (MeRIP-seq) and RNA sequencing (RNA-seq) were utilized to acquire the first transcriptome-wide profiling of the mA methylome map in IMPA followed by bioinformatics analysis.

Results: In this study, we obtained mA methylation maps of IMPA samples and normal adjacent tissues through MeRIP-seq. In total, 25,490 mA peaks associated with 13,735 genes were detected in the IMPA group, whereas 33,930 mA peaks associated with 18,063 genes were detected in the control group. Peaks were primarily enriched within coding regions and near stop codons with AAACC and GGAC motifs. Moreover, functional enrichment analysis demonstrated that mA-containing genes were significantly enriched in cancer and metabolism relevant pathways. Furthermore, we identified a relationship between the mA methylome and the RNA transcriptome, indicating a mechanism by which mA modulates gene expression.

Conclusions: Our study is the first to provide comprehensive and transcriptome-wide profiles to determine the potential roles played by mA methylation in IMPA. These results may open new avenues for in-depth research elucidating the mA topology of IMPA and the molecular mechanisms governing the formation and progression of IMPA.

Citing Articles

Pan-cancer Analysis Reveals m6A Variation and Cell-specific Regulatory Network in Different Cancer Types.

Lin Y, Li J, Liang S, Chen Y, Li Y, Cun Y Genomics Proteomics Bioinformatics. 2024; 22(4).

PMID: 38970366 PMC: 11514823. DOI: 10.1093/gpbjnl/qzae052.


Synchronous profiling of mRNA N6-methyladenosine modifications and mRNA expression in high-grade serous ovarian cancer: a pilot study.

Yang L, Liu J, Jin Y, Xing J, Zhang J, Chen X Sci Rep. 2024; 14(1):10427.

PMID: 38714753 PMC: 11076553. DOI: 10.1038/s41598-024-60975-x.


YTHDF2 promotes gallbladder cancer progression and gemcitabine resistance via m6A-dependent DAPK3 degradation.

Bai X, Chen J, Zhang W, Zhou S, Dong L, Huang J Cancer Sci. 2023; 114(11):4299-4313.

PMID: 37700438 PMC: 10637062. DOI: 10.1111/cas.15953.


GPX8 deficiency-induced oxidative stress reprogrammed m6A epitranscriptome of oral cancer cells.

Chen X, Yuan L, Zhang L, Chen L, He Y, Wang C Epigenetics. 2023; 18(1):2208707.

PMID: 37170591 PMC: 10184595. DOI: 10.1080/15592294.2023.2208707.


Identification of m6a-related signature genes in esophageal squamous cell carcinoma by machine learning method.

Shang Q, Kong W, Huang W, Xiao X, Hu W, Yang Y Front Genet. 2023; 14:1079795.

PMID: 36733344 PMC: 9886874. DOI: 10.3389/fgene.2023.1079795.


References
1.
Karthiya R, Khandelia P . m6A RNA Methylation: Ramifications for Gene Expression and Human Health. Mol Biotechnol. 2020; 62(10):467-484. DOI: 10.1007/s12033-020-00269-5. View

2.
Wu K . The role of miRNA biogenesis and DDX17 in tumorigenesis and cancer stemness. Biomed J. 2020; 43(2):107-114. PMC: 7283569. DOI: 10.1016/j.bj.2020.03.001. View

3.
Kondoh K, Tsuji N, Kamagata C, Sasaki M, Kobayashi D, Yagihashi A . A novel aspartic protease gene, ALP56, is up-regulated in human breast cancer independently from the cathepsin D gene. Breast Cancer Res Treat. 2003; 78(1):37-44. DOI: 10.1023/a:1022149226430. View

4.
Ping X, Sun B, Wang L, Xiao W, Yang X, Wang W . Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 2014; 24(2):177-89. PMC: 3915904. DOI: 10.1038/cr.2014.3. View

5.
Wu R, Yao Y, Jiang Q, Cai M, Liu Q, Wang Y . Epigallocatechin gallate targets FTO and inhibits adipogenesis in an mRNA mA-YTHDF2-dependent manner. Int J Obes (Lond). 2018; 42(7):1378-1388. DOI: 10.1038/s41366-018-0082-5. View